Adcetris is a CD30-directed antibody-drug conjugate (ADC) consisting of three components: 1. The chimeric IgG1 antibody cAC10 is specific for human CD30. 2. The microtubule disrupting agent MMAE. 3. A protease-cleavable linker that covalently attaches MMAE to cAC10. This medicine is recommended to use the medicine Adcetris in treating patients who have Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after the failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates and patients with Systemic Anaplastic Large Cell Lymphoma after the failure of at least one prior multi-agent chemotherapy regimen.
Lena Denvir
Charles Bailey
Stride University
Expert Car Repair Shop
Online Course Platform
Sm605 Plataforma
8s8eucom
Ys88 Vncom
58win1 Us
33win Downloadcom